Volume 22 Issue 9
Sep.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(9): 1512-1517
YU Jiexin, LIU Yanli, LI Xingyu. Clinical research of Lucentis combined with fortify spleen for fluid retention removement recipe in the treatment of retinal vein occlusion macular edema[J]. Chinese Journal of General Practice, 2024, 22(9): 1512-1517. doi: 10.16766/j.cnki.issn.1674-4152.003671
Citation: YU Jiexin, LIU Yanli, LI Xingyu. Clinical research of Lucentis combined with fortify spleen for fluid retention removement recipe in the treatment of retinal vein occlusion macular edema[J]. Chinese Journal of General Practice, 2024, 22(9): 1512-1517. doi: 10.16766/j.cnki.issn.1674-4152.003671
shu

Clinical research of Lucentis combined with fortify spleen for fluid retention removement recipe in the treatment of retinal vein occlusion macular edema

doi: 10.16766/j.cnki.issn.1674-4152.003671

  • Department of Ophthalmology, the First Affiliated Hospital of Zhejiang Chinese Medicine University (Zhejiang Provincial Hospital of TCM), Hangzhou, Zhejiang 310006, China

Funds:

 2021ZQ039

  • Received Date: 2024-02-24
    Abstract
  •   Objective  To explore the clinical effects of Lucentis combined with fortify spleen for fluid retention removement recipe and its prognostic indicators in the treatment of retinal vein occlusion macular edema (RVO-ME).  Methods  A total of 60 patients with RVO-ME visiting the First Affiliated Hospital of Zhejiang Chinese Medical University from October 2021 to October 2022 were randomly divided into a combination treatment group and a conventional treatment group. Each included 30 cases. All patients were given intravitreal injection of Ranibizumab for three months. The combined treatment group was given oral granules administration of self-prepared Chinese medicine recipe for fortifying spleen to remove fluid retention, while the control group was treated with placebo granules. The inflammatory markers of peripheral blood, best corrected visual acuity (BCVA), high reflection signal (HRF) in OCT images, macular central thickness (CMT), sub-retinal fluid (SRF), and cystoid macular edema (CME) before and after the treatment in the two groups were compared. Those indexes were also compared between patients with and without recurrent ME, The group with recurrent ME included 20 patients, while the group without recurrent ME included 40 patients.  Results  After 3 months of treatment, the systemic immune inflammatory index (SII), neutrophil-to-lymphocyte ratio (NLR), HRF, and CMT in the combined treatment group were significantly lower than those in the conventional treatment group (P < 0.05). The combined treatment group has significantly higher resolution rates of SRF (88.9% vs. 50.0%) and CME (63.0% vs. 25.0%, P < 0.05). The RVO-ME recurrence rate in the combined treatment group was 20.0%, significantly lower than the conventional group (46.7%, P < 0.05). HRF and CMT descended more significantly in patients without recurrent ME than those with recurrent ME (P < 0.05). The ROC curve indicates patients with baseline CMT < 497.50 μm (P=0.010) and HRF < 15.5 (P=0.021) had a lower probability of edema recurrence and better BCVA.  Conclusion  Combined treatment of Lucentis with self-prepared Chinese medicine granules improves the efficacy and reduces recurrence in the treatment of RVO-ME. Patients with CMT < 497.50 μm and HRF≤15 before treatment have a better prognosis.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    ZHANG W, LIU Y, SANG A. Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis[J]. BMC Ophthalmol, 2022, 22(1): 472. doi: 10.1186/s12886-022-02682-7
    [2]
    孙梅, 郝晓凤, 谢立科, 等. 视网膜静脉阻塞的相关危险因素研究进展[J]. 中国中医眼科杂志, 2021, 31(6): 445-448.

    SUN M, HAO X F, XIE L K, et al. Research progress on risk factors related to retinal vein occlusion[J]. China Journal of Chinese Ophthalmology, 2021, 31(6): 445-448.
    [3]
    LEE J H, KIM S H, KIM E. Influence of smoking and controlled medical conditions on the risks of branch retinal vein occlusion in South Korea: a population-based study[J]. Ophthalmic Epidemiol, 2024: 1-8. DOI: 10.1080/09286586.2024.2321902.
    [4]
    HUSUM Y S, BRATEN R H, SAETHER E M, et al. Intravitreal anti-vascular endothelial growth factor therapy for retinal diseases in Norway from 2011 to 2021: a combined registry and survey study[J]. Acta Ophthalmol, 2023: 1-11. DOI: 10.1111/aos.16598.
    [5]
    DARABUS D M, PAC C P, ROSCA C, et al. Macular dynamics and visual acuity prognosis in retinal vein occlusions-ways to connect[J]. Rom J Ophthalmol, 2023, 67(3): 312-324.
    [6]
    QIN H F, SHI F J, ZHANG C Y, et al. Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion[J]. Int J Ophthalmol, 2022, 15(8): 1296-1304. doi: 10.18240/ijo.2022.08.11
    [7]
    MICHL M, LIU X, KAIDER A, et al. The impact of structural optical coherence tomography changes on visual function in retinal vein occlusion[J]. Acta Ophthalmol, 2021, 99(4): 418-426. doi: 10.1111/aos.14621
    [8]
    CHATAIRALLI I, KAZANTZIS D, KROUPIS C, et al. The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion[J]. Int Ophthalmol, 2022, 42(11): 3449-3457. doi: 10.1007/s10792-022-02344-z
    [9]
    ZUO W, CHEN T, SONG J, et al. Assessment of systemic immune-inflammation index levels in patients with retinal vein occlusion[J]. Ocul Immunol Inflamm, 2023, 31(3): 491-495. doi: 10.1080/09273948.2022.2032199
    [10]
    HIRABAYASHI K, TANAKA M, IMAI A, et al. Development of a novel model of central retinal vascular occlusion and the therapeutic potential of the adrenomedullin-receptor activity-modifying protein 2 system[J]. Am J Pathol, 2019, 189(2): 449-466. doi: 10.1016/j.ajpath.2018.10.021
    [11]
    ZHOU Y, QI J, LIU H, et al. Increased intraocular inflammation in retinal vein occlusion is independent of circulating immune mediators and is involved in retinal oedema[J]. Front Neurosci, 2023, 17: 1186025. DOI: 10.3389/fnins.2023.1186025.
    [12]
    KAZANTZIS D, MACHAIROUDIA G, KROUPIS C, et al. Complete blood count-derived inflammation indices and retinal vein occlusion: a case-control study[J]. Ophthalmol Ther, 2022, 11(3): 1241-1249. doi: 10.1007/s40123-022-00511-0
    [13]
    KAZANTZIS D, SERGENTANIS T N, MACHAIROUDIA G, et al. Correlation between imaging morphological findings and laboratory biomarkers in patients with retinal vein occlusion[J]. Ophthalmol Ther, 2023, 12(2): 1239-1249. doi: 10.1007/s40123-023-00677-1
    [14]
    SHI K, SUN X, ZHANG J. Optical coherence tomography angiography characteristics serve as retinal vein occlusion therapeutic biomarkers for dexamethasone intravitreal implant[J]. Dis Markers, 2021, 2021: 3510036. DOI: 10.1155/2021/3510036.
    [15]
    MAT NOR M N, GUO C X, GREEN C R, et al. Hyper-reflective dots in optical coherence tomography imaging and inflammation markers in diabetic retinopathy[J]. J Anat, 2023, 243(4): 697-705. doi: 10.1111/joa.13889
    [16]
    HUANG H, JANSONIUS N M, CHEN H, et al. Hyperreflective dots on oct as a predictor of treatment outcome in diabetic macular edema: a systematic review[J]. Ophthalmol Retina, 2022, 6(9): 814-827. doi: 10.1016/j.oret.2022.03.020
    [17]
    CHUNG Y R, LEE S Y, KIM Y H, et al. Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia[J]. Acta Diabetol, 2020, 57(7): 861-866. doi: 10.1007/s00592-020-01495-8
    [18]
    YAO C, WANG M, ZHU W, et al. Joint segmentation of multi-class hyper-reflective foci in retinal optical coherence tomography images[J]. IEEE Trans Biomed Eng, 2022, 69(4): 1349-1358. doi: 10.1109/TBME.2021.3115552
    [19]
    ZHU R, XIAO S, ZHANG W, et al. Comparison of hyperreflective foci in macular edema secondary to multiple etiologies with spectral-domain optical coherence tomography: an observational study[J]. BMC Ophthalmol, 2022, 22(1): 352. doi: 10.1186/s12886-022-02575-9
    [20]
    刘珊珊, 郭杰, 李宗艾, 等. 泽泻化学成分及药理作用研究进展[J]. 中国中药杂志, 2020, 45(7): 1578-1595.

    LIU S S, GUO J, LI Z A, et al. Advances in studies on chemical compositions of Alismatis Rhizoma and their biological activities[J]. China Journal of Chinese Materia Medica, 2020, 45(7): 1578-1595.
    [21]
    马艳春, 胡建辉, 吴文轩, 等. 黄芪化学成分及药理作用研究进展[J]. 中医药学报, 2022, 50(4): 92-95.

    MA Y C, HU J H, WU W X, et al. Research progress on chemical constituents and pharmacological effects of Astragalus[J]. Acta Chinese Medicine and Pharmacology, 2022, 50(4): 92-95.
    [22]
    冯科冉, 李伟霞, 王晓艳, 等. 丹参化学成分、药理作用及其质量标志物(Q-Marker)的预测分析[J]. 中草药, 2022, 53(2): 609-618.

    FENG K R, LI W X, WANG X Y, et al. Chemical components and pharmacological action for Salviae Mitiorrhizae Radix et Rhizoma and predictive analysis on quality markers[J]. Chinese Traditional and Herbal Drugs, 2022, 53(2): 609-618.
    [23]
    李姿毅, 夏源, 王军义. 黄芪甲苷抗氧化应激分子机制的研究进展[J]. 广东药科大学学报, 2022, 38(4): 118-122.

    LI Z Y, XIA Y, WANG J Y. Progress of the antioxidant molecular mechanism of astragalosideⅣ[J]. Journal of Guangdong Pharmaceutical University, 2022, 38(4): 118-122.
    [24]
    LIANG X, SHEN B, OU Z, et al. Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion[J]. Front Med (Lausanne), 2022, 9: 930508. DOI: 10.3389/fmed.2022.930508.
    [25]
    TAKANO Y, NOMA H, YASUDA K, et al. Retinal blood flow as a predictor of recurrence of macular edema after intravitreal ranibizumab injection in central retinal vein occlusion[J]. Ophthalmic Res, 2021, 64(6): 1013-1019. doi: 10.1159/000519150
    [26]
    马若楠, 吴正正, 高明雪, 等. 基于通下活血法治疗视网膜静脉阻塞性黄斑水肿[J]. 浙江中医药大学学报, 2023, 47(6): 643-646.

    MA R N, WU Z Z, GAO M X, et al. Treatment of RVO-ME based on means of activating blood circulation and purgating Method[J]. Journal of Zhejiang Chinese Medical University, 2023, 47(6): 643-646.
    [27]
    钱雄, 张银敏, 陈锴. 运脾补血方辅助治疗缺铁性贫血患儿的临床效果分析[J]. 中华全科医学, 2023, 21(1): 88-91. doi: 10.16766/j.cnki.issn.1674-4152.002819

    QIAN X, ZHANG Y M, CHEN K. Clinical effect of Yunpi Buxue Decoction in the treatment of children with iron deficiency anaemia[J]. Chinese Journal of General Practice, 2023, 21(1): 88-91. doi: 10.16766/j.cnki.issn.1674-4152.002819
    [28]
    左军, 祁天立, 胡晓阳. 茯苓化学成分及现代药理研究进展[J]. 中医药学报, 2023, 51(1): 110-114.

    ZUO J, QI T L, HU X Y. Research progress on chemical constituents and modern pharmacology of Poria cocos[J]. Acta Chinese Medicine and Pharmacology, 2023, 51(1): 110-114.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (26) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return